T1	Gene_or_protein	18 50	epidermal growth factor receptor
T2	Gene_or_protein	53 59	EGFR )
T3	Chemical	65 86	monoclonal antibodies
T4	Chemical	105 131	inhibitors of the tyrosine
T5	Gene_or_protein	105 152	inhibitors of the tyrosine kinase ( TK ) domain
T6	Chemical	105 173	inhibitors of the tyrosine kinase ( TK ) domain of the receptor have
T7	Pharmacodynamic_phenotype	217 249	antitumor activities in patients
T8	Disease	255 293	non-small-cell lung cancer ( NSCLC ) .
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T1	Arg2:T7
R7	isEquivalentTo	Arg1:T2	Arg2:T1
R8	isAssociatedWith	Arg1:T2	Arg2:T3
R9	isAssociatedWith	Arg1:T2	Arg2:T4
R10	isAssociatedWith	Arg1:T2	Arg2:T5
R11	isAssociatedWith	Arg1:T2	Arg2:T6
R12	isAssociatedWith	Arg1:T2	Arg2:T7
R13	isAssociatedWith	Arg1:T2	Arg2:T8
R14	decreases	Arg1:T3	Arg2:T1
R15	decreases	Arg1:T3	Arg2:T2
R16	influences	Arg1:T3	Arg2:T7
R17	treats	Arg1:T3	Arg2:T8
R18	decreases	Arg1:T4	Arg2:T1
R19	decreases	Arg1:T4	Arg2:T2
R20	influences	Arg1:T4	Arg2:T3
R21	influences	Arg1:T4	Arg2:T7
R22	treats	Arg1:T4	Arg2:T8
R23	decreases	Arg1:T5	Arg2:T1
R24	decreases	Arg1:T5	Arg2:T2
R25	influences	Arg1:T5	Arg2:T3
R26	influences	Arg1:T5	Arg2:T4
R27	influences	Arg1:T5	Arg2:T7
R28	treats	Arg1:T5	Arg2:T8
R29	decreases	Arg1:T6	Arg2:T1
R30	decreases	Arg1:T6	Arg2:T2
R31	influences	Arg1:T6	Arg2:T3
R32	influences	Arg1:T6	Arg2:T4
R33	influences	Arg1:T6	Arg2:T5
R34	influences	Arg1:T6	Arg2:T7
R35	treats	Arg1:T6	Arg2:T8
R36	decreases	Arg1:T7	Arg2:T1
R37	decreases	Arg1:T7	Arg2:T2
R38	influences	Arg1:T7	Arg2:T3
R39	treats	Arg1:T7	Arg2:T8
R40	decreases	Arg1:T8	Arg2:T1
R41	decreases	Arg1:T8	Arg2:T2
